Galectin Therapeutics (GALT) Corporate presentation summary

Strategic focus and pipeline

• Developing galectin-3 inhibitors for chronic liver diseases and cancer, with a focus on MASH cirrhosis and portal hypertension.

• Belapectin, a novel galectin-3 inhibitor, has Fast Track Designation and patent protection through 2032.

• Pipeline includes belapectin for MASH cirrhosis, combination therapy with Keytruda for oncology, and discovery of oral galectin-3 inhibitors.

• Only company exclusively targeting MASH cirrhosis and portal hypertension.

Market opportunity and unmet need

• MASH cirrhosis affects 3–5% of the global population, with 5M U.S. patients and no FDA-approved treatments.

• MASH cirrhosis is expected to become the leading cause for liver transplants in the U.S.

• Peak U.S. sales for belapectin estimated at $18B, with high adoption potential due to limited treatment options.

Clinical trial results: NAVIGATE and GT-026

• NAVIGATE enrolled advanced MASH cirrhosis patients with portal hypertension and no baseline varices.

• Belapectin 2 mg reduced new varices incidence by 43.2% (ITT) and 48.9% (per protocol) vs placebo at 18 months.

• Significant reduction in new varices in U.S. patients and those on GLP-1 therapy.

• Non-invasive biomarkers (LSM, ELF) and fibrosis markers showed less worsening with belapectin.

• No dose-response benefit at higher doses; 2 mg dose demonstrated optimal efficacy.